Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1982-04-15
1987-03-03
Moyer, Donald B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3141
Patent
active
046475710
ABSTRACT:
L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.
REFERENCES:
patent: 3974031 (1976-08-01), Yamada et al.
patent: 4006057 (1977-02-01), Sano et al.
patent: 4335210 (1982-06-01), Meister et al.
Kaneko et al., Synthesis and Properties of 2-Oxothiazolidin-4-Carboxylic Acid . . . Bull. Chem. Soc. Jap., vol. 37: 242-244, 1964.
Inui, Selective Cleavage of Cysteine & Peptides, Bull Chem. Soc. Jap., vol. 44: 2515-2520, 1971.
Meister Alton
Williamson Joanne M.
Cornell Research Foundation
Moyer Donald B.
Rollins John W.
LandOfFree
Cysteine delivery composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine delivery composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine delivery composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1016855